drug discovery

LEADXPRO SCIENTISTS CHART THE FUTURE OF STRUCTURE BASED DRUG DISCOVERY

In a series of scientific publications leadXpro AG scientists explore the utility of cutting-edge X-ray technologies for the discovery of new therapeutics. Medicines...

More details More details

Two well-known techniques + new application field = breakthrough of the year

This fall, Dr. Tim Grüne from the Paul Scherrer Institute (PSI) together with Crystallise! AG published the results of their joint project, presenting...

More details

InterAx raises CHF 3 Mio for the commercialization of its systems biology platform

InterAx Biotech AG is a spin off from the ETH Zürich and Paul Scherrer Institute (PSI). The company assists GPCR drug candidate design and selection by...

More details

Structure-based drug discovery drives the development of novel treatment options

Drug development is a long and unpredictable process that requires high levels of investment, endurance and state-of-the-art technology. Basic research...

More details

State-of-the-art bioinformatics for better drug discovery

The effect a drug has on the human body depends on how well its active substance find its way to the targeted cells in the body, and on the chemical reactions...

More details

Biosensors Technology Platform for efficient lead discovery

In April 2016, the team at InterAx Biotech AG mounted the nameplate of a newly-born company on the wall of PARK INNOVAARE’s deliveryLAB, thus giving...

More details

High-tech companies learned first-hand about PARK INNOVAARE

PARK INNOVAARE-Management, existing shareholders and spin-off-companies already operating at PARK INNOVAARE informed potential new shareholders about current...

More details
Subscribe to drug discovery